Background: In the last two decades, extreme obesity and its comorbidities have often been treated with bariatric surgery.
Objective: Our goal was to compare the levels of GLP-1 in individuals who are severely obese three months after undergoing any of the three more frequent bariatric methods: sleeve gastrectomy (SG), Roux en Y gastric bypass (RYGB), or intragastric balloon (IGB).
Patients and Methods: This is prospective research being done at Benha University Hospital for people with obesity and type 2 diabetes who have been recruited 3 months prior to having any bariatric surgeries. Patients were subjected to measurement ofWC, BMI and laboratory assay of HbA1c, fasting plasma glucose (FPG), fasting insulin, HOMA-IR, ALT, AST, glucagon-like peptide-1 (GLP-1) and lipid profile before and after 3 months of procedures.
Results: There was significant improvement of FPG, and HbA1c in RYGB operation in comparison with other bariatric procedures. Fasting insulin was substantially lower in the RYGB surgery than the in SG and IGB (p ˂ 0.05) with substantial improvements of HOMA-IR for RYGB surgery (p ˂ 0.05). In RYGB surgery, there was highly substantial increase in GLP-1 levels compared to SG and IGB procedures (p <0.001). The change in BMI were significant (p ˂0.001) in RYGB but waist circumference did not change significantly after 3 months of any of three procedures.
Conclusion: Our results demonstrated that GLP-1 values were increased after RYGB compared to SG and IGB after three months of the procedures.